

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****[Docket No. 00N-1303]****Agency Information Collection Activities; Announcement of OMB Approval; Agreement for Shipment of Devices for Sterilization****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Agreement for Shipment of Devices for Sterilization" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 14, 2000 (65 FR 55634), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0131. The approval expires on November 30, 2003. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: December 5, 2000.

Margaret M. Dotzel,
Associate Commissioner for Policy.

[FR Doc. 00-31590 Filed 12-11-00; 8:45 am]

BILLING CODE 4160-01-F**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****[Docket No. 00N-1328]****Agency Information Collection Activities; Announcement of OMB Approval; Latex Condoms; User Labeling; Expiration Dating****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Latex Condoms; User Labeling; Expiration Dating" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 25, 2000 (65 FR 57617), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0352. The approval expires on November 30, 2003. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: December 5, 2000.

Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 00-31593 Filed 12-11-00; 8:45 am]
BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****[Docket No. 00N-1359]****Agency Information Collection Activities; Announcement of OMB Approval; Affirmation of Generally Recognized as Safe (GRAS) Status****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Affirmation of Generally Recognized as Safe (GRAS) Status" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 25, 2000 (65 FR 57616), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0132. The approval expires on November 30, 2003. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: December 5, 2000.

Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 00-31594 Filed 12-11-01; 8:45 am]
BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****Advisory Committees; Notice of Meetings****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2001. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM's recommendation.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5496.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the

Federal Register and FDA implemented the recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Since the schedule is tentative, amendments to this notice

will not be published in the **Federal Register**. However, changes to the schedule will be posted on the FDA Advisory Committees' home page located at www.fda.gov/oc/advisory/default.htm. The FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2001. You may also obtain up-to-date meeting information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area):

Committee Name	Dates of Meetings	Advisory Committee 5-Digit Information Line Code
OFFICE OF THE COMMISSIONER Science Board to the Food and Drug Administration	April 13 November 16	12603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH Allergenic Products Advisory Committee	March 5 October 29	12388
Biological Response Modifiers Advisory Committee	January 18-19 April 5-6 July 12-13 October 25-26	12389
Blood Products Advisory Committee	March 15-16 July 26-27 September 20-21 December 13-14	19516
Transmissible Spongiform Encephalopathies Advisory Committee	January 18-19 June 28-29 October 25-26	12392
Vaccines and Related Biological Products Advisory Committee	January 30-31 March 8-9 May 16-17 September 13-14 November 28-29	12391
CENTER FOR DRUG EVALUATION AND RESEARCH Advisory Committee for Pharmaceutical Science	April 23-24 August 13-14 October 29-30	12539
Advisory Committee for Reproductive Health Drugs	June 1	12537
Anesthetic and Life Support Drugs Advisory Committee	January 25-26 May 10-11 September 13-14	12529
Anti-Infective Drugs Advisory Committee	January 29-30	12530
Antiviral Drugs Advisory Committee	January 11 April 26-27 July 23-24 October 22-23 December 6-7	12531
Arthritis Advisory Committee	February 7-9 April 19-20 August 16-17 October 11-12 December 6-7	12532
Cardiovascular and Renal Drugs Advisory Committee	February 8-9 May 17-18 October 18-19	12533
Dermatologic and Ophthalmic Drugs Advisory Committee	February 5 June 5 August 14 September 18 December 9-10	12534
Drug Abuse Advisory Committee	No meetings are planned	12535
Endocrinologic and Metabolic Drugs Advisory Committee	February 22-23 April 26-27 July 26-27 September 20-21 November 8-9	12536
Gastrointestinal Drugs Advisory Committee	March 29-30	12538
Medical Imaging Drugs Advisory Committee	March 1 July 2	12540

Committee Name	Dates of Meetings	Advisory Committee 5-Digit Information Line Code
Nonprescription Drugs Advisory Committee	May 10–11	12541
Oncologic Drugs Advisory Committee	March 13–14 June 7–8	12542
Peripheral and Central Nervous System Drugs Advisory Committee	March 13–15	12543
Pharmacy Compounding Advisory Committee	March 29–30 June 28–29 September 13–14	12440
Psychopharmacologic Drugs Advisory Committee	February 14–15	12544
Pulmonary-Allergy Drugs Advisory Committee	January 18–19 April 26–27 September 6–7	12545
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION Food Advisory Committee	April 23–24 September 24–25	10564
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Device Good Manufacturing Practice Advisory Committee	No meetings are planned	12398
Medical Devices Advisory Committee		
Anesthesiology and Respiratory Therapy Devices Panel	June 14–15	12624
Circulatory System Devices Panel	February 5 April 2–3 June 25–26 September 10–11 December 3–4	12625
Clinical Chemistry and Clinical Toxicology Devices Panel	January 17 May 9 July 11 October 24–25 December 5–6	12514
Dental Products Panel	April 3–4 August 14–15 November 13–14	12518
Dispute Resolution Panel	Will meet as needed	10232
Ear, Nose, and Throat Devices Panel	February 22–23 June 11–12 October 11–12	12522
Gastroenterology-Urology Devices Panel	March 9 June 29 September 24–25 December 10–11	12523
General and Plastic Surgery Devices Panel	February 7 May 15–16 September 24–25 December 10–11	12519
General Hospital and Personal Use Devices Panel	February 12–13 May 17–18 August 2–3 November 1–2	12520
Hematology and Pathology Devices Panel	February 26 April 23 July 30 October 8	12515
Immunology Devices Panel	March 16 June 15 September 14 December 3	12516
Microbiology Devices Panel	March 8–9 July 19–20 October 25–26 December 6–7	12517
Molecular and Clinical Genetics Panel	March 9 June 8 September 7 December 7	10231
Neurological Devices Panel	February 8–9 May 17–18 November 15–16	12513
Obstetrics-Gynecology Devices Panel	January 29–30 April 30–May 1 July 16–17 October 15–16	12524

Committee Name	Dates of Meetings	Advisory Committee 5-Digit Information Line Code
Ophthalmic Devices Panel	March 15–16 May 17–18 July 19–20 September 20–21 November 29–30	12396
Orthopaedic and Rehabilitation Devices Panel	January 18–19 May 10–11 August 9–10 November 1–2	12521
Radiological Devices Panel	February 5 May 14 August 13 November 5	12526
National Mammography Quality Assurance Advisory Committee	April 23 September 10	12397
Technical Electronic Product Radiation Safety Standards Committee	May 16–17	12399
CENTER FOR VETERINARY MEDICINE Veterinary Medicine Advisory Committee	February 20–21 September 12–13	12548
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH Advisory Committee on Special Studies Relating to the Possible Long- Term Health Effects of Phenoxy Herbicides and Contaminants	December 6–7 May 10–11	12560
Science Board to the National Center for Toxicological Research	June 7–8	12559

Dated: December 5, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–31589 Filed 12–11–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225–00–800]

Memorandum of Understanding Between the Food and Drug Administration and the Centers for Disease Control and Prevention

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the Centers for Disease Control and Prevention. The purpose of the MOU is to provide a framework for coordination and collaborative efforts, and provide the principles and procedures by which information exchanges shall take place.

DATES: The agreement became effective June 26, 2000.

FOR FURTHER INFORMATION CONTACT:

Ellen F. Morrison, Office of Regulatory Affairs (HFC–130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5660.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and MOU's between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this MOU.

Dated: December 3, 2000.

Margaret M. Dotzel,

Associate Commissioner for Policy.

BILLING CODE 4160–01–F